Citations

Mayo Clinic

Showing 10 of 108523 citations.

Effect of bariatric surgery on cardiometabolic risk in elderly patients: A population‐based study
Batsis, John A. , Miranda, William R. , Prasad, Chaithra , Collazo–Clavell, Maria L. , Sarr, Michael G. , Somers, Virend K. , López-Jiménez, Francisco

Geriatrics & Gerontology International | May 28, 2015 | Volume: 16 | Issue: 5 | Pages: 618-624

10.1111/ggi.12527 | PMID 26017642 Get It

AimObesity is a major cardiovascular (CV) risk factor. Bariatric surgery (BSx) is an approved therapeutic alternative for class II–III obesity, but little evidence focuses on older adults. We assessed the effect of BSx on cardiometabolic variables and long‐term CV risk in older adults.MethodsWe carried out a population‐based, observational study from 1990–2009, of 40 consecutive elderly (age ≥60 years) residents of Olmsted County, MN, USA, with class II–III obesity treated with BSx at a University‐based, academic health center. Data were obtained from the Rochester Epidemiology Project. Metabolic syndrome (MetS) was defined using American Heart Association/National Heart, Lung, Blood Institute (AHA/NHLBI) criteria (increased triglycerides, low high‐density lipoprotein, increased blood pressure, increased glucose and body mass index as a modified measure of obesity instead of waist circumference). Change in CV risk factors, MetS prevalence, and impact on predicted CV risk using the Framingham risk score was ascertained at 1 year postoperatively and assessed statistically.ResultsMean age and body mass index were 64.4 ± 3.7 and 45.0 ± 6.3 kg/m2, respectively, and 28 out of 40 (70%) were women. One participant died during the 11‐month study period after BSx from respiratory complications related to BSx, and one participant died at 2 years. Percentage of excess weight loss decreased by 57.5% at 1 year. Prevalence 1 year after BSx decreased for diabetes (57.5% to 22.5%; P < 0.03), hypertension 87.5% to 73.7% (P = 0.003), dyslipidemia (80% to 42.5%; P < 0.001) and sleep apnea (62.5% to 23.7%; P < 0.001).MetS prevalence decreased from 80% to 45% (P < 0.002). Baseline risk was 14.1%, which changed at follow up at 8.2%.ConclusionsIn older adults, BSx induces considerable weight loss, improves CV risk factors, decreases MetS prevalence and is an effective treatment in this population. Geriatr Gerontol Int 2016; 16: 618–624.
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D
Zonszein, Joel , Lombardero, M. , Ismail‐Beigi, Faramarz , Foucher, Suzy, Groenewoud, Yolanda, Cushing, Gary W., Wajchenberg, B L, Genuth, Saul, Group, BARI 2D Study, Palumbo, Pasquale, Palumbo, Pasquale J , Group, BARI 2D Study

Journal of Diabetes Research | May 28, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-12

10.1155/2015/129891 | PMID 26106623 Get It

Glycemic management is central in prevention of small vessel and cardiovascular complications in type 2 diabetes. With the plethora of newer medications and recommendations for a patient centered approach, more information is necessary to match the proper drug to each patient. We showed that BARI 2D, a five-year trial designed to compare two different glycemic treatment strategies, was suitable for assessing different responses according to different phenotypic characteristics. Treatment with insulin sensitizing medications such as thiazolidinediones and metformin was more effective in improving glycemic control, particularly in the more insulin resistant patient, when compared to the insulin provision strategy using insulin and or sulfonylureas. Triglyceride and high density lipoprotein ratio (TG/HDL-cholesterol ratio) was found to be a readily available and practical biomarker that helps to identify the insulin resistant patient. These results support the concept that not all medications for glycemic control work the same in all patients. Thus, tailored therapy can be done using phenotypic characteristics rather than a “one-size-fits-all approach.”
Evaluation of the FilmArray Blood Culture ID Panel on Biofilms Dislodged from Explanted Arthroplasties for Prosthetic Joint Infection Diagnosis
Vasoo, Shawn , Cunningham, Scott A. , Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Hanssen, Arlen D. , Osmon, Douglas R. , Berbari, Elie F. , Patel, Robin , Abdel, Matthew P. , Patel, Robin , Cunningham, Scott A

Journal of Clinical Microbiology | May 28, 2015 | Volume: 53 | Issue: 8 | Pages: 2790-2792

10.1128/jcm.01333-15 | PMID 26019200 Get It

Standard Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Reagents May Inactivate Potentially Hazardous Bacteria
Cunningham, Scott A. , Patel, Robin , Patel, Robin , Cunningham, Scott A

Journal of Clinical Microbiology | May 28, 2015 | Volume: 53 | Issue: 8 | Pages: 2788-2789

10.1128/jcm.00957-15 | PMID 26019211 Get It

Fast and furious: Why all CARs are not made equal
Dronca, Roxana

Science Translational Medicine | May 28, 2015 | Volume: 7 | Issue: 289 | Pages: No page available

10.1126/scitranslmed.aac5086 Get It

4-1BB can mitigate CAR endodomain-induced T cell exhaustion and prolong T cell survival.
Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma
Penheiter, Alan R. , Erdoğan, Sibel , Hart, Steven N. , Lima, Joema Felipe , Rohakhtar, Fariborz Rakhshan, O’Brien, Daniel R. , Bamlet, William R. , Wuertz, Ryan E. , Smyrk, Thomas C. , Vasmatzis, George , Bender, Claire E., Carlson, Stephanie K., Felipe Lima, Joema, Rakhshan Rohakhtar, Fariborz, O'Brien, Daniel R, Murphy, Stephen J. , Couch, Fergus J. , Bamlet, William R , Hart, Steven N

BioMed Research International | May 28, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-10

10.1155/2015/593572 | PMID 26106611 Get It

We used a target-centric strategy to identify transporter proteins upregulated in pancreatic ductal adenocarcinoma (PDAC) as potential targets for a functional imaging probe to complement existing anatomical imaging approaches. We performed transcriptomic profiling (microarray and RNASeq) on histologically confirmed primary PDAC tumors and normal pancreas tissue from 33 patients, including five patients whose tumors were not visible on computed tomography. Target expression was confirmed with immunohistochemistry on tissue microarrays from 94 PDAC patients. The best imaging target identified was SLC6A14 (a neutral and basic amino acid transporter). SLC6A14 was overexpressed at the transcriptional level in all patients and expressed at the protein level in 95% of PDAC tumors. Very little is known about the role of SLC6A14 in PDAC and our results demonstrate that this target merits further investigation as a candidate transporter for functional imaging of PDAC.
Altruistic reasoning in adolescent-parent dyads considering participation in a hypothetical sexual health clinical trial for adolescents
Chávez, Noé Rubén , Williams, Camille Y. , Ipp, Lisa, Catallozzi, Marina , Rosenthal, Susan L. , Breitkopf, Carmen Radecki

Research Ethics | May 27, 2015 | Volume: 12 | Issue: 2 | Pages: 68-79

10.1177/1747016115587963 | PMID 27019669 Get It

Altruism is a well-established reason underlying research participation. Less is known about altruism in adolescent-parent decision-making about clinical trials enrolling healthy adolescents. This qualitative investigation focused on identifying spontaneous statements of altruism within adolescent-parent (dyadic) discussions of participation in a hypothetical phase I clinical trial related to adolescent sexual health. Content analysis revealed several response patterns to each other’s altruistic reasoning. Across 70 adolescent-parent dyads in which adolescents were 14 to 17 years of age and 91% of their parents were mothers, a majority (61%) of dyadic discussions included a statement reflecting altruism. Parents responded to adolescents’ statements of altruism more frequently than adolescents responded to parents’ statements. Responses included: expresses concern, reiterates altruistic reasoning, agrees with altruistic reasoning, and adds to/expands altruistic reasoning. Since an altruistic perspective was often balanced with concerns about risk or study procedures, researchers cannot assume that altruism will directly lead to study participation. Optimizing the informed consent process for early phase clinical trials involving healthy adolescents may include supporting parents to have conversations with their adolescents which will enhance their capacity to consider all aspects of trial participation.
Lymphadenopathy With Ipsilateral Eye Involvement
Acheampong, Benjamin , Loar, Robert W. , Boyce, Thomas G.

Clinical Pediatrics | May 27, 2015 | Volume: 54 | Issue: 9 | Pages: 910-912

10.1177/0009922815588824 | PMID 26016836 Get It

One‐year clinical outcomes after sirolimus‐eluting coronary stent implantation in diabetics enrolled in the worldwide e‐SELECT registry
Bartorelli, Antonio L. , Assenza, Gabriele Egidy , Abizaid, Alexandre , Banning, Adrian , Džavík, Vladimír , Ellis, Stephen G. , Gao, Runlin, Holmes, David R. , Jeong, Myung Ho , Legrand, Victor , Spaulding, Christian , Worthley, Stephen G., Urban, Philip , Investigators, for the e‐SELECT, Gao, Runlin, Jeong, Myung Ho , Neumann, Franz–Josef , Investigators, for the e‐SELECT, Banning, Adrian , Abizaid, Alexandre

Catheterization and Cardiovascular Interventions | May 27, 2015 | Volume: 87 | Issue: 1 | Pages: 52-62

10.1002/ccd.26026 | PMID 26012537 Get It

BackgroundDiabetes mellitus has worse outcome after percutaneous coronary intervention.AimWe assessed stent thrombosis (ST), major adverse cardiac events (MACE), and major bleeding rates at 1 year after implantation of sirolimus‐eluting stents (SES) in patients with diabetes mellitus in a large multicenter registry.MethodsFrom May 2006 to April 2008, 15,147 unselected consecutive patients were enrolled at 320 centers in 56 countries in a prospective, observational registry after implantation of ≥ 1 SES. Source data were verified in 20% randomly chosen patients at > 100 sites. Adverse events were adjudicated by an independent Clinical Event Committee.ResultsComplete follow‐up at 1 year was obtained in 13,693 (92%) patients, 4,577 (30%) of whom were diabetics. Within diabetics, 1,238 (9%) were insulin‐treated diabetics (ITD). Diabetics were older (64 vs. 62 years, P < 0.001), with higher incidence of major coronary risk factors, co‐morbidities, and triple‐vessel coronary artery disease. Coronary lesions had smaller reference vessel diameter (2.88 ± 0.46 vs. 2.93 ± 0.45 mm, P < 0.001) and were more often heavily calcified (26.1% vs. 22.6%, P < 0.001). At 1 year, diabetics had higher MACE rate (6.8% vs. 3.9%, P < 0.001) driven by ITD (10.6% vs. 5.5%, P < 0.001). Finally, diabetics had significant increase in ST (1.7% vs. 0.7%, P < 0.001), principally owing to ITD (3.4% vs. 1.1%, P < 0.001). There was an overall low risk of major bleeding during follow‐up, without significant difference among subgroups.ConclusionsIn the e‐SELECT registry, diabetics represented 30% of patients undergoing SES implantation and had significantly more co‐morbidities and complex coronary lesions. Although 1‐year follow‐up documented good overall outcome in diabetics, higher ST and MACE rates were observed, mainly driven by ITD. © 2015 Wiley Periodicals, Inc.
How we provide thawed plasma for trauma patients
Stubbs, James R. , Zielinski, Martin D. , Berns, Kathleen S., Badjie, Karafa S., Tauscher, Craig D. , Hammel, Scott A., Zietlow, Scott P., Jenkins, Donald H.

Transfusion | May 27, 2015 | Volume: 55 | Issue: 8 | Pages: 1830-1837

10.1111/trf.13156 | PMID 26013588 Get It

Almost 50% of trauma‐related fatalities within the first 24 hours of injury are related to hemorrhage. Improved survival in severely injured patients has been demonstrated when massive transfusion protocols are rapidly invoked as part of a therapeutic approach known as damage control resuscitation (DCR). DCR incorporates the early use of plasma to prevent or correct trauma‐induced coagulopathy. DCR often requires the transfusion of plasma before determination of the recipient's ABO group. Historically, group AB plasma has been considered the “universal donor” plasma product. At our facility, the number of AB plasma products produced on an annual basis was found to be inadequate to support the trauma service's DCR program. A joint decision was made by the transfusion medicine and trauma services to provide group A thawed plasma (TP) for in‐hospital and prehospital DCR protocols. A description of the implementation of group A TP into the DCR program is provided as well as outcome data pertaining to the use of TP in trauma patients.